Floatz logo

Fosifloxuridine Nafalbenamide

Colorectal Carcinoma

NuCana plcSmall moleculePhase 1/2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
73/ 100

Competitive context

161 Active assets in the Colorectal Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Mayo Clinic
Phase 2BBB
FLUOROURACILUM
City of Hope Medical Center
Phase 4BB
Eloxatin
First Affiliated Hospital of Zhejiang University
Phase 4BB
MITOMYCIN C
City of Hope Medical Center
Phase 3BB
Capecitabine
First Affiliated Hospital of Zhejiang University
Phase 4BB

View all 50 →

Same molecule, other indications

Fosifloxuridine Nafalbenamide is also rated in:

colorectal neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →
colorectal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →